Meeting
2020 ASCO Virtual Scientific Program
Mismatch between mortality burden and number of FDA registration trials in highly lethal cancers.
Authors
Bishal Gyawali
Brigham and Women's Hospital, Boston, MA
Bishal Gyawali , Peter C. Yang , Sam Rubinstein , Martin W. Schoen , Ali Raza Khaki , Jeremy Lyle Warner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Health and Regulatory Policy
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2072)
DOI
10.1200/JCO.2020.38.15_suppl.2072
Abstract #
2072
Poster Bd #
64
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Female representation in clinical trials leading to FDA cancer drug approvals for gastrointestinal (GI) cancers between 2008 to 2018.
First Author: Shehara Ramyalini Mendis
Poster
2023 ASCO Breakthrough
Disparities in African-American patient enrollment in pivotal phase 3 immunotherapy trials that led to FDA drug approval in patients with non-small cell lung cancer.
First Author: Chimezie Ubbaonu
Poster
2023 ASCO Annual Meeting
Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population.
First Author: Aanika Balaji
Poster
2022 ASCO Annual Meeting
NHS-Galleri Trial Design: Equitable study recruitment tactics for targeted population-level screening with a multi-cancer early detection (MCED) test.
First Author: Charles Swanton